Lafora diseaseEpidemiology, pathophysiology and management

被引:0
|
作者
Thomas S. Monaghan
Norman Delanty
机构
[1] Beaumont Hospital and Royal College of Surgeons in Ireland,Epilepsy Programme and Consultant Neurologist, Department of Neurology and Neuroscience
来源
CNS Drugs | 2010年 / 24卷
关键词
Vigabatrin; Ketogenic Diet; Zonisamide; Piracetam; Neuronal Ceroid Lipofuscinoses;
D O I
暂无
中图分类号
学科分类号
摘要
Lafora disease is a rare, fatal, autosomal recessive, progressive myoclonic epilepsy. It may also be considered as a disorder of carbohydrate metabolism because of the formation of polyglucosan inclusion bodies in neural and other tissues due to abnormalities of the proteins laforin or malin. The condition is characterized by epilepsy, myoclonus and dementia. Diagnostic findings on MRI and neurophysiological testing are not definitive and biopsy or genetic studies may be required. Therapy in Lafora disease is currently limited to symptomatic management of the epilepsy, myoclonus and intercurrent complications. With a greater understanding of the pathophysiological processes involved, there is justified hope for future therapies.
引用
收藏
页码:549 / 561
页数:12
相关论文
共 50 条
  • [1] Tangier DiseaseEpidemiology, Pathophysiology, and Management
    Mariarita Puntoni
    Francesco Sbrana
    Federico Bigazzi
    Tiziana Sampietro
    American Journal of Cardiovascular Drugs, 2012, 12 (5) : 303 - 311
  • [2] Darier’s DiseaseEpidemiology, Pathophysiology, and Management
    Susan M. Cooper
    Susan M. Burge
    American Journal of Clinical Dermatology, 2003, 4 : 97 - 105
  • [3] Postural Instability in Patients with Parkinson’s DiseaseEpidemiology, Pathophysiology and Management
    Samuel D. Kim
    Natalie E. Allen
    Colleen G. Canning
    Victor S. C. Fung
    CNS Drugs, 2013, 27 : 97 - 112
  • [4] Lafora Disease Epidemiology, Pathophysiology and Management
    Monaghan, Thomas S.
    Delanty, Norman
    CNS DRUGS, 2010, 24 (07) : 549 - 561
  • [5] Gastrointestinal Motility Problems in Patients with Parkinson’s DiseaseEpidemiology Pathophysiology and Guidelines for Management
    Ronald F. Pfeiffer
    Eamonn M. M. Quigley
    CNS Drugs, 1999, 11 : 435 - 448
  • [6] Sleep Disturbances in Patients with Alzheimer’s DiseaseEpidemiology,Pathophysiology and Treatment
    Michael V. Vitiello
    Soo Borson
    CNS Drugs, 2001, 15 : 777 - 796
  • [7] Depression in Patients with Parkinson’s DiseaseEpidemiology, Pathophysiology and Treatment Options
    Theresa A. Zesiewicz
    Robert A. Hauser
    CNS Drugs, 2000, 13 : 253 - 264
  • [8] Physical and Mental Fatigue in Parkinson’s DiseaseEpidemiology, Pathophysiology and Treatment
    Jau-Shin Lou
    Drugs & Aging, 2009, 26 : 195 - 208
  • [9] Sleep Disorders in Parkinson’s DiseaseEpidemiology and Management
    Mark Stacy
    Drugs & Aging, 2002, 19 : 733 - 739
  • [10] Sleep Disorders in Patients with Parkinson’s DiseaseEpidemiology and Management
    Jan P. Larsen
    Elise Tandberg
    CNS Drugs, 2001, 15 : 267 - 275